Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom.

Noe MH, Grewal SK, Shin DB, Ogdie A, Takeshita J, Gelfand JM.

J Eur Acad Dermatol Venereol. 2017 Oct;31(10):1674-1680. doi: 10.1111/jdv.14310. Epub 2017 Jun 1.

PMID:
28485831
2.

Long-term change in incidence and risk factors of cirrhosis and hepatocellular carcinoma in Crete, Greece: a 25-year study.

Karageorgos SA, Stratakou S, Koulentaki M, Voumvouraki A, Mantaka A, Samonakis D, Notas G, Kouroumalis EA.

Ann Gastroenterol. 2017;30(3):357-363. doi: 10.20524/aog.2017.0135. Epub 2017 Mar 23.

3.

Management of HBV and HBV/HDV-Associated Liver Cirrhosis.

Höner Zu Siederdissen C, Cornberg M.

Visc Med. 2016 Apr;32(2):86-94. doi: 10.1159/000445518. Epub 2016 Apr 12. Review.

4.

Anti-fibro-hepatocarcinogenic Chinese herbal medicines: A mechanistic overview.

Boye A, Yang Y, Asenso J, Wei W.

J Intercult Ethnopharmacol. 2016 Jun 14;5(3):278-89. doi: 10.5455/jice.20160530032814. eCollection 2016 Jun-Aug. Review.

5.

KASL clinical practice guidelines: management of chronic hepatitis B.

Korean Association for the Study of the Liver.

Clin Mol Hepatol. 2016 Mar;22(1):18-75. doi: 10.3350/cmh.2016.22.1.18. Epub 2016 Mar 28. Review. No abstract available.

6.

Clinical Characteristics of Patients with Cryptogenic Hepatocellular Carcinoma in a Hepatitis B Virus-Endemic Area.

Kwak HW, Park JW, Koh YH, Lee JH, Yu A, Nam BH.

Liver Cancer. 2016 Feb;5(1):21-36. doi: 10.1159/000367756. Epub 2015 Dec 15.

7.

Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation.

Cenderello G, Artioli S, Viscoli C, Pasa A, Giacomini M, Giannini B, Dentone C, Nicolini LA, Cassola G, Di Biagio A.

Clinicoecon Outcomes Res. 2015 Dec 31;8:15-21. doi: 10.2147/CEOR.S93641. eCollection 2016.

8.

Contributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesis.

Ohkoshi S, Hirono H, Watanabe K, Hasegawa K, Yano M.

World J Hepatol. 2015 Dec 8;7(28):2834-40. doi: 10.4254/wjh.v7.i28.2834. Review.

9.

The new era of hepatitis C virus therapy.

Al-Judaibi B.

Saudi J Gastroenterol. 2015 Nov-Dec;21(6):345-54. doi: 10.4103/1319-3767.170947. Review.

10.

Molecular docking studies of phytochemicals from Phyllanthus niruri against Hepatitis B DNA Polymerase.

Mohan M, James P, Valsalan R, Nazeem PA.

Bioinformation. 2015 Sep 30;11(9):426-31. doi: 10.6026/97320630011426. eCollection 2015.

11.

Establishing the link between hepatitis B virus infection and colorectal adenoma.

Patel BB, Lipka S, Shen H, Davis-Yadley AH, Viswanathan P.

J Gastrointest Oncol. 2015 Oct;6(5):492-7. doi: 10.3978/j.issn.2078-6891.2015.049.

12.

Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis.

Honda K, Seike M, Murakami K.

World J Hepatol. 2015 Oct 8;7(22):2404-10. doi: 10.4254/wjh.v7.i22.2404. Review.

13.

Improved Survival in Patients with Viral Hepatitis-Induced Hepatocellular Carcinoma Undergoing Recommended Abdominal Ultrasound Surveillance in Ontario: A Population-Based Retrospective Cohort Study.

Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC.

PLoS One. 2015 Sep 23;10(9):e0138907. doi: 10.1371/journal.pone.0138907. eCollection 2015.

14.

Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease.

Russo FP, Rodríguez-Castro K, Scribano L, Gottardo G, Vanin V, Farinati F.

World J Hepatol. 2015 May 18;7(8):1097-104. doi: 10.4254/wjh.v7.i8.1097. Review.

15.

Management of patients with hepatitis B in special populations.

Cholongitas E, Tziomalos K, Pipili C.

World J Gastroenterol. 2015 Feb 14;21(6):1738-48. doi: 10.3748/wjg.v21.i6.1738. Review.

16.

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H.

J Clin Oncol. 2015 Feb 20;33(6):550-8. doi: 10.1200/JCO.2014.57.9151. Epub 2014 Dec 15.

17.

Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity.

Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SF, Thomas CJ, Jiang JK, Meck C, Hirsch DR, D'Erasmo MP, Suyabatmaz DM, Murelli RP, Tavis JE.

Antimicrob Agents Chemother. 2015 Feb;59(2):1070-9. doi: 10.1128/AAC.04617-14. Epub 2014 Dec 1.

18.

The impact of vaccination and antiviral therapy on hepatitis B and hepatitis D epidemiology.

Goyal A, Murray JM.

PLoS One. 2014 Oct 14;9(10):e110143. doi: 10.1371/journal.pone.0110143. eCollection 2014.

19.

Clinical outcomes of compensated and decompensated cirrhosis: A long term study.

Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA.

World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504.

20.

Does antiviral therapy reduce complications of cirrhosis?

Chung GE, Lee JH, Kim YJ.

World J Gastroenterol. 2014 Jun 21;20(23):7306-11. doi: 10.3748/wjg.v20.i23.7306. Review.

Supplemental Content

Support Center